Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance - ScienceDirect
ESMO 2022: Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial
Breast Cancer - ESMO 2022 Highlights - Expert Analysis - ESMO 2022 - Oncology - Clinical Care Options
Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple-negative breast cancer on Vimeo
PDF) Preoperative robotic radiosurgery for early breast cancer: Results of the phase II ROCK trial (NCT03520894)
Jose Fernando Moura, PhD on Twitter: "#esmo22 proffered abstracts # breastcancer DATA trial ➕ extend AI; GIM trial longer results 👍🏻 to dose dense and 👎🏻to add 5️⃣FU; ADAPT trial and ADAPTcycle 👍🏻to
ESMO 2022: Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial
Breast Cancer - ESMO 2022 Highlights - Expert Analysis - ESMO 2022 - Oncology - Clinical Care Options
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials | npj Breast Cancer
Cancers | Free Full-Text | Loco-Regional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancer Patients Undergoing Front-Line Chemotherapy
CLINICAL IMPACT SERIES: SABCS 2021 - Metastatic BC
ESMO 2022: Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial
ESMO 2022: Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial
Co-administration of H-ferritin-doxorubicin and Trastuzumab in neoadjuvant setting improves efficacy and prevents cardiotoxicity in HER2 + murine breast cancer model | Scientific Reports
ICIs Exhibit Activity in Triple-Negative Breast Cancer With Higher TIL Levels - Cancer Therapy Advisor
Paolo Tarantino on Twitter: "Two weeks to #ESMO22. Plenty of important breast cancer studies to be presented at the Congress, some that will immediately inform practice. Here's 10 key abstracts to keep
ESMO 2022: Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial
Natera presents colorectal, breast cancer data at ESMO 2022 | LabPulse.com
The role of immune checkpoint inhibitors in triple-negative breast cancer: recent developments and future perspectives
Cancers | Free Full-Text | Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond
A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma - Clinical Lymphoma, Myeloma and Leukemia
Addition of Venetoclax to Bortezomib/Dexamethasone in Relapsed or Refractory Multiple Myeloma - The ASCO Post
JCM | Free Full-Text | Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC)
JCM | Free Full-Text | Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges
ESMO 2022: Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial
